The latest in the MS generics fight.
Biogen is a big pharmaceutical company that produces a half-dozen MS drugs. Among them are Tysabri, Avonex and Tecfidera. And Biogen is doing all it can to protect its turf, particularly when it comes to its best seller, Tecfidera.
Last month the company filed lawsuits against several pharmaceutical companies that are trying to develop generic versions of Tecfidera. According to an article in the Boston Business Journal, in the five days between June 26-30 Biogen filed 26 patent-infringement lawsuits in federal court against several competitors, including Mylan Pharmaceuticals and Sandoz.
The patents involved in the lawsuits expire over the next 10 years. In its suit against Sandoz, Biogen claims it “will suffer substantial and irreparable harm for which there is no adequate remedy at law” if the court allows a generic version of Tecfidera to be marketed right now.
Tecfidera accounted for close to $4 billion in sales for Biogen last year. That’s more than a third of the company’s total drug sales. I wrote about the cost of Tecfidera back in January, noting that Biogen was hiking its price, and that of two other drugs, by about 8 percent. That increase followed other hikes in preceding months.
Read full article: Fighting in Court Over MS Generics
|Read Full Article: Fighting in Court Over MS Generics|